Eli Lilly and Co (XSWX:LLY) Beginning Cash Position: CHF5,722 Mil (As of Mar. 2026)


XSWX:LLY Eli Lilly and Co XSWX:LLY
100 GF Score
Price CHF970.00
GF Value CHF1,132.28
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Eli Lilly and Co Beginning Cash Position?

Eli Lilly and Co XSWX:LLY 100 Beginning Cash Position is CHF5,722 Mil as of Mar. 2026. GuruFocus rates XSWX:LLY with a GF Score™ of 100/100 and a GF Value™ of CHF1,132.28 (Modestly Undervalued). The stock has 6 warning signs investors should review.

Eli Lilly and Co's Beginning Cash Position for the quarter that ended in Mar. 2026 was CHF5,722 Mil.

Eli Lilly and Co's quarterly Beginning Cash Position increased from Sep. 2025 (CHF2,688 Mil) to Dec. 2025 (CHF7,803 Mil) but then declined from Dec. 2025 (CHF7,803 Mil) to Mar. 2026 (CHF5,722 Mil).

Eli Lilly and Co's annual Beginning Cash Position increased from Dec. 2023 (CHF1,788 Mil) to Dec. 2024 (CHF2,513 Mil) and increased from Dec. 2024 (CHF2,513 Mil) to Dec. 2025 (CHF2,604 Mil).

Eli Lilly and Co Beginning Cash Position Related Terms

Eli Lilly and Co Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Eli Lilly and Co's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eli Lilly and Co Beginning Cash Position Chart

Eli Lilly and Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3,368.19 3,557.32 1,787.54 2,513.42 2,604.27

Eli Lilly and Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,887.61 2,515.55 2,687.56 7,802.85 5,722.10
XSWX:LLY
100GF Score
Eli Lilly and Co XSWX:LLY
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Eli Lilly and Co Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of CHF5,722 Mil mean?
Eli Lilly and Co (XSWX:LLY) has a Beginning Cash Position of CHF5,722 Mil as of Mar. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Eli Lilly and Co and its competitors.
Is Eli Lilly and Co's Beginning Cash Position too high?
Eli Lilly and Co's current Beginning Cash Position is CHF5,722 Mil. Overall, Eli Lilly and Co has a GF Score™ of 100/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eli Lilly and Co's Beginning Cash Position compare to JNJ and ABBV?
Eli Lilly and Co's Beginning Cash Position of CHF5,722 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Drug Manufacturers company?
A good Beginning Cash Position depends on the Drug Manufacturers industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Eli Lilly and Co and its competitors. Eli Lilly and Co's current Beginning Cash Position is CHF5,722 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eli Lilly and Co stock overvalued right now?
Based on GuruFocus' analysis, Eli Lilly and Co (XSWX:LLY) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF1,132.28, compared to a current price of CHF970.00 — trading 14.3% below its estimated fair value. The current Beginning Cash Position is CHF5,722 Mil. Eli Lilly and Co's overall GF Score™ is 100/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Eli Lilly and Co (XSWX:LLY), the current Beginning Cash Position is CHF5,722 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Eli Lilly and Co (XSWX:LLY) Overvalued in 2026?

Based on GuruFocus' analysis, Eli Lilly and Co stock appears to be undervalued. The current stock price of CHF970.00 is trading 14.3% below its estimated GF Value™ of CHF1,132.28. GuruFocus considers Eli Lilly and Co to be Modestly Undervalued.

Key valuation signals for XSWX:LLY:

  • Beginning Cash Position: CHF5,722 Mil
  • GF Value™: CHF1,132.28 vs. price of CHF970.00 (14.3% below fair value)
  • GF Score™: 100/100 with 6 warning signs

No single metric tells the full story. See the XSWX:LLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Eli Lilly and Co Business Description

Address Lilly Corporate Center, Indianapolis, IN, USA, 46285
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
100GF Score

Get the complete analysis for XSWX:LLY

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF970.00
Price
CHF1,132.28
GF Value